Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy.

Tytuł:
KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy.
Autorzy:
Shekh-Ahmad T; UCL Institute of Neurology, University College London, Queen Square, London WC1N, UK.
Eckel R; UCL Institute of Neurology, University College London, Queen Square, London WC1N, UK.
Dayalan Naidu S; Jacqui Wood Cancer Centre, Division of Cancer Research, School of Medicine, University of Dundee, Dundee, Scotland, UK.
Higgins M; Jacqui Wood Cancer Centre, Division of Cancer Research, School of Medicine, University of Dundee, Dundee, Scotland, UK.
Yamamoto M; Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Japan.
Dinkova-Kostova AT; Jacqui Wood Cancer Centre, Division of Cancer Research, School of Medicine, University of Dundee, Dundee, Scotland, UK.; Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kovac S; UCL Institute of Neurology, University College London, Queen Square, London WC1N, UK.; Department of Neurology, University of Muenster, Muenster 48149, Germany.
Abramov AY; UCL Institute of Neurology, University College London, Queen Square, London WC1N, UK.
Walker MC; UCL Institute of Neurology, University College London, Queen Square, London WC1N, UK.
Źródło:
Brain : a journal of neurology [Brain] 2018 May 01; Vol. 141 (5), pp. 1390-1403.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Oxford : Oxford University Press
Original Publication: London.
MeSH Terms:
Anticonvulsants/*therapeutic use
Epilepsy/*metabolism
Epilepsy/*therapy
Kelch-Like ECH-Associated Protein 1/*metabolism
Animals ; Animals, Newborn ; Anticonvulsants/chemistry ; Cells, Cultured ; Cerebral Cortex/cytology ; Disease Models, Animal ; Epilepsy/chemically induced ; Excitatory Amino Acid Agonists/toxicity ; Gene Expression Regulation/drug effects ; Gene Expression Regulation/genetics ; Glutathione/metabolism ; Kainic Acid/toxicity ; Kelch-Like ECH-Associated Protein 1/genetics ; Male ; Membrane Potential, Mitochondrial/drug effects ; Membrane Potential, Mitochondrial/genetics ; Mice, Transgenic ; Mutation/genetics ; Neuroglia/drug effects ; Neuroglia/metabolism ; Neurons/drug effects ; Neurons/metabolism ; Oxidative Stress/drug effects ; Oxidative Stress/genetics ; Rats ; Rats, Sprague-Dawley ; Triterpenes/chemistry ; Triterpenes/therapeutic use
Grant Information:
18644 United Kingdom CRUK_ Cancer Research UK; BB/L01923X/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council
Substance Nomenclature:
0 (Anticonvulsants)
0 (Excitatory Amino Acid Agonists)
0 (Keap1 protein, mouse)
0 (Kelch-Like ECH-Associated Protein 1)
0 (Triterpenes)
G69Z98951Q (omaveloxolone)
GAN16C9B8O (Glutathione)
SIV03811UC (Kainic Acid)
Entry Date(s):
Date Created: 20180315 Date Completed: 20190708 Latest Revision: 20240210
Update Code:
20240210
DOI:
10.1093/brain/awy071
PMID:
29538645
Czasopismo naukowe
Hippocampal sclerosis is a common acquired disease that is a major cause of drug-resistant epilepsy. A mechanism that has been proposed to lead from brain insult to hippocampal sclerosis is the excessive generation of reactive oxygen species, and consequent mitochondrial failure. Here we use a novel strategy to increase endogenous antioxidant defences using RTA 408, which we show activates nuclear factor erythroid 2-related factor 2 (Nrf2, encoded by NFE2L2) through inhibition of kelch like ECH associated protein 1 (KEAP1) through its primary sensor C151. Activation of Nrf2 with RTA 408 inhibited reactive oxygen species production, mitochondrial depolarization and cell death in an in vitro model of seizure-like activity. RTA 408 given after status epilepticus in vivo increased ATP, prevented neuronal death, and dramatically reduced (by 94%) the frequency of late spontaneous seizures for at least 4 months following status epilepticus. Thus, acute KEAP1 inhibition following status epilepticus exerts a neuroprotective and disease-modifying effect, supporting the hypothesis that reactive oxygen species generation is a key event in the development of epilepsy.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies